ProPhase Labs, Inc. shares had a trading volume of 52 in the last trading session. Overall, volume was down 99.57% under the stocks normal daily volume.
Short traders are more bullish on ProPhase Labs, Inc. of late as shown by the downtick in short interest. The firm experienced a fall in short interest of -66.25% as of October 13, 2017 from the last reporting period. Short shares decreased from 9,815 to 3,313 over that period. Days to cover decreased -1.0 to 0.0 and the percentage of shorted shares is 0.00% as of October 13.
These funds have shifted positions in (PRPH). Commonwealth Equity Services, Inc trimmed its stake by shedding 6,500 shares a decrease of 37.1% as of 06/30/2017. Commonwealth Equity Services, Inc now controls 11,000 shares valued at $22,000. The value of the position overall is down by 45.0%. Creative Planning added to its ownership by buying 1,850 shares an increase of 1,233.3%. Creative Planning controls 2,000 shares worth $4,000. The total value of its holdings increased inf%.
Ubs Group Ag downsized its holdings by selling 10,075 shares a decrease of 95.0% in the quarter. Ubs Group Ag owns 525 shares with a value of $1,000. The total value of its holdings decreased 95.8%. Acadian Asset Management LLC augmented its investment by buying 6,035 shares an increase of 144.3% from 06/30/2017 to 09/30/2017. Acadian Asset Management LLC currently owns 10,216 shares valued at $22,000. The total value of its holdings increased 144.4%.
In the market the company is trading unchanged since yesterday’s close of $2.17. It is currently trading at $2.17 a bit higher than $2.15, the stock’s 50 day moving average and which is marginally over the 200 day moving average of $2.08. The 50 day moving average moved up $0.03 and the 200 day average was up $0.10.
The company currently has a P/E ratio of 0.9052 and the market cap is 35.15M.
ProPhase Labs, Inc., launched on August 24, 1989, manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is involved in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products..